PEGylated aspartyl-tRNA synthetase polypeptides
US9822353B2 · kind B2 · utility
2Cited by
75References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2012 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | Aug 20, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.